Klotho-based therapeutic program for cognitive impairment
preclinicalDevelop a Klotho-based treatment to support cognitive vitality and manage age-related cognitive impairment, including neurodegenerative disease contexts such as Alzheimer's and Parkinson's disease mentioned in the supplied evidence.
Proprietary synthetic subcutaneous formulation of alpha-Klotho protein therapeutic; development is supported by Klotho genetics and published preclinical/clinical-association research on cognition, APOE4, amyloid, Parkinson's cognition, and Alzheimer's models.
$35 million Series A announced in 2025 to advance the longevity protein program; human trials estimated to begin in 2026 pending ongoing manufacturing.
Company-supplied evidence describes Klotho as circulating in blood, protecting the brain and reducing toxicity, and notes that the KL-VS allele is associated with boosted circulating Klotho. Listed publications report Klotho-related cognitive findings in nonhuman primates, Parkinson's disease, APOE4/Alzheimer's contexts, and mouse Alzheimer's models, but no clinical results for JN-0413 are supplied.